Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Consensus PT from Brokerages

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have been given a consensus recommendation of “Buy” by the five analysts that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $16.00.

A number of research firms recently weighed in on TENX. StockNews.com began coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating for the company. William Blair began coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. Leerink Partners started coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Finally, Guggenheim started coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TENX. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics in the 3rd quarter worth about $101,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics in the 3rd quarter worth about $173,000. Finally, Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics in the 3rd quarter worth about $288,000. 1.67% of the stock is currently owned by institutional investors.

Tenax Therapeutics Stock Down 3.7 %

TENX opened at $6.24 on Wednesday. The company has a fifty day simple moving average of $5.53 and a 200 day simple moving average of $4.31. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $21.46.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.